Lantheus Holdings Business Summary

Lantheus Holdings, Inc. (LNTH) is a premier radiopharmaceutical company that generates revenue primarily through the commercialization of diagnostic imaging agents and nuclear medicine products used to detect and treat cardiovascular and oncological diseases. The company’s business is organized into two core segments: Radiopharmaceutical Oncology, anchored by its market-leading PSMA-PET imaging agent PYLARIFY for prostate cancer, and Precision Diagnostics, which includes the ultrasound enhancing agent DEFINITY and the TechneLite generator. Following the strategic divestiture of its SPECT business to SHINE Technologies in early 2026, Lantheus has pivoted toward high-growth therapeutic and diagnostic pipelines, including its MK-6240 tau imaging agent for Alzheimer’s and LNTH-2501 for neuroendocrine tumors. Within the competitive landscape, Lantheus maintains a dominant position in the U.S. PSMA-PET market, holding an estimated 60% share while competing directly with global healthcare giants such as GE HealthCare, Novartis, and specialized peers like Telix Pharmaceuticals and Blue Earth Diagnostics. Originally founded in 1956 as New England Nuclear Corporation, the modern iteration of Lantheus is led by Mary Anne Heino, who resumed leadership as Interim CEO and Executive Chairperson in January 2026 after previously serving as CEO from 2015 to 2024. She is supported by Robert J. Marshall Jr., a veteran of Zimmer Biomet who serves as CFO and Treasurer, and Dr. Ludger Dinkelborg, the Head of Research and Development who joined following the 2025 acquisition of Life Molecular Imaging. The executive team also includes Chief Science Officer Dr. Jean-Claude Provost and Chief Commercial Officer Amanda Morgan. The company’s strategic direction is overseen by a board featuring industry experts like Lead Independent Director Julie McHugh and Dr. P.K. Morrow. Lantheus is backed by a strong base of institutional investors, including The Vanguard Group, BlackRock, and Farallon Capital Management, reflecting its status as a stabilized leader in the rapidly evolving radiopharmaceutical sector.